A Study to Assess the Efficacy of a 5-day, Once Daily 10- mg PBF-680 Oral Administration Course to Attenuate Allergen Bronchoprovocation-induced Late Asthmatic Responses (LAR) in Asthmatic Patients Controlled on Low-to-medium Dose Inhaled Corticosteroid Maintenance Monotherapy and Inhaled Short Acting Beta-2 Agonist as Rescue Bronchodilator
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2016
At a glance
- Drugs PBF 680 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Palobiofarma
- 15 Sep 2016 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 15 Sep 2016 Planned End Date changed from 1 Sep 2016 to 1 Sep 2017.
- 14 Oct 2015 New trial record